ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2017 Financial Results
To access the live call by phone, dial 719-325-4907; the conference ID
is 6498153. The call also may be accessed through the Investors section
of the Company's website, www.immunogen.com.
Following the live webcast, a replay of the call will be available at
the same location through
About
ImmunoGen is a clinical-stage
biotechnology company that develops targeted cancer therapeutics using
its proprietary ADC technology. The Company's lead product candidate,
mirvetuximab soravtansine, is in a Phase 3 trial for FRα-positive
platinum-resistant ovarian cancer, and is in a Phase 1b/2 trial in
combination regimens for earlier-stage disease. ImmunoGen has three
additional clinical-stage product candidates, two of which are being
developed in collaboration with Jazz Pharmaceuticals. ImmunoGen's ADC
technology is also used in Roche's marketed product, Kadcyla®,
and in programs in development by Amgen, Bayer, Biotest, CytomX,
Kadcyla® is a registered trademark of
View source version on businesswire.com: http://www.businesswire.com/news/home/20171020005050/en/
For Investors
sarah.kiely@immunogen.com
or
For
Media
courtney.okonek@immunogen.com
or
FTI
Consulting, Inc.
Robert Stanislaro, 212-850-5657
robert.stanislaro@fticonsulting.com
Source:
News Provided by Acquire Media